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We evaluated the chemopreventive eﬀect of nonsteroidal anti-inﬂammatory drug (NSAID) use in head and neck squamous cell
carcinomas (HNSCC) by conducting a case-control study based on the administration of a standardized questionnaire to 71
incidentHNSCCcasesandsamenumberofhealthycontrols.NSAIDusewasassociatedwitha75%reductioninriskofdeveloping
HNSCC.AsigniﬁcantriskreductionwasnotedinassociationwithfrequencyofNSAIDuse.Restrictingtheanalysistoaspirinusers
revealed a signiﬁcant 90% reduction in risk of developing HNSCC. This study provides evidence for a signiﬁcant reduction in the
risk of developing HNSCC in users of NSAIDs, and speciﬁcally aspirin users.
1.Introduction
Head and neck cancer refers to carcinoma of the upper
aerodigestive tract and the most common form is squa-
mous cell carcinoma (HNSCC). In the United States alone,
HNSCC accounts for 3% of newly diagnosed cancer cases
[1–3] and the major known risk factors are smoking and
chewing tobacco and alcohol consumption [4, 5], but
recently the role of human papillomavirus (HPV) 16 has
been highlighted [6]. Despite advances in treatment, patients
with HNSCC develop recurrent disease, and 15% to 25%
developsecondprimarymalignancieswithin5yearsofinitial
diagnosis [7]. It is therefore crucial that chemopreventive
measures other than tobacco and alcohol cessation should be
further investigated.
One area in cancer chemoprevention which has gained
signiﬁcant recognition is the role of non-steroidal anti-
inﬂammatory drugs (NSAIDs). The inhibitory eﬀects of
NSAIDs in HNSCC have been of interest since Panje [8]
reported tumor regression of HNSCC in patients taking
NSAIDs. The use of NSAIDs such as aspirin, indomethacin,
and celecoxib has been associated with reduced risk of
developing colorectal, esophageal, lung, gastric, breast, and
ovarian cancers [9–15]. Randomized controlled trials and
recent meta-analysis demonstrated that the use of aspirin
decreases the incidence of colorectal adenomas and intraep-
ithelial neoplasia in patients with previous history of col-
orectal cancer [15, 16]. Preliminary study supported the
use of aspirin as adjuvant therapy to improve survival in
subsets of postesophagectomy patients [17], while there was
no evidence of a protective eﬀect of aspirin and nonaspirin
NSAID use in relation to esophageal adenocarcinoma in two
independent studies [18, 19] .Ap r o t e c t i v ee ﬀect of NSAID
use and gastric noncardia adenocarcinoma but not with
gastric cardia cancer has also been reported [18]. While
the exact mechanism through which NSAIDs contribute to
chemoprevention is incompletely understood, it is thought
to involve the inhibition of the enzyme cyclooxygenase-
2 (COX-2) of the arachadonic acid metabolism pathway
[9]. There are only a few reported investigations of the
chemopreventive eﬀects of NSAIDs in HNSCC [11, 20–22]
and the results have been inconsistent. The largest case-
control study within the US examined 529 cancer patients
and529hospital-basedcontrolsmatchedforage,gender,and2 International Journal of Otolaryngology
smoking status. The authors demonstrated that the use of
aspirin was associated with a 25% reduction in the risk of
head and neck cancer [21].
In order to further evaluate the relationship between
NSAIDs and chemoprevention in HNSCC, we performed
a case-control study based on the administration of a
standardized questionnaire examining NSAID use. The goal
of our investigation was to determine whether the frequency
of NSAID use is lower in patients presenting with established
H N S C Cc o m p a r e dt os a m ea g ea n dg e n d e rc o n t r o l s .
2.MaterialsandMethods
2.1. Study Population and Data Collection. The study popu-
lation consisted of HNSCC cases (N = 71) that were newly
diagnosed and pathologically conﬁrmed and recruited as
part of an ongoing study at the Lombardi Comprehensive
Cancer Center, at Georgetown University Medical School
(GUMC) between 2003 and 2007. Inclusion criteria were
age greater than 18, no previous history of malignancy,
no prior treatment with chemoradiation or surgery, and
ﬂuency in English in order to consent to the study. Controls
(N = 71) consisted of healthy individuals with no history
of cancer that were either accompanying patients on their
visit to Georgetown University Hospital or participated
in the National Lung Screening Trial (NLST) at George-
town University, a trial that aimed to evaluate radiological
methods for detection of lung cancer in a population of
cancer-free individuals. Participation rates were 65% for
cases and 68% for controls. After informed consent was
obtained, cases and controls received a structured, in-person
interview assessing medical and cancer history, tobacco use,
and alcohol use. Cases and controls were matched one to
o n eo na g ew i t h i n1 0y e a r s ,g e n d e r ,a n dh i s t o r yo ft o b a c c o
use. A subject was considered an “ever smoker” if they
had smoked >100 cigarettes in their lifetime and a “never
smoker” if they responded negatively to the question. A
subject was considered an “ever alcohol user” if they had
consumed more than 12 alcoholic beverages per year in their
entire life. Cumulative use of cigarettes and alcohol (pack-
years, drink-years, resp.) was computed by multiplying the
amount consumed per day by the number of years of
usage. Information on occupational history, family medical
history, recent nutritional supplements and caﬀeine intake,
socioeconomic characteristics, and NSAID use history was
also collected. More speciﬁcally, the questionnaire inquired
about the frequency (never, occasional, daily) and reason
of NSAID use (headache, arthritis, heart disease, stroke, or
other). Among daily users, information on age at initiation
of NSAID use, quantities, type, and change of patterns of
use over time was collected, and this allowed calculation of
a combined measure of dosage and duration by computing
NSAID tablet years (tablets/day × years of use).
2.2. Data Analysis. Statistical analyses were carried out using
the SAS software, version 9.2 (SAS Institute Inc. Cary,
NC). For diﬀerences in demographic distributions and other
characteristics between cases and controls, no statistical tests
were performed because of the study design that involved
1:1 case: control pairing and would require matched pairs to
be excluded if a variable is missing for any of the paired sub-
jects. Characteristics of case and control groups separately
stratiﬁed by NSAID use were compared using t-tests for
continuous characteristics, Fisher’s exact test for categorical
characteristics with a cell count of 5 or less, and chi-square
tests for all other categorical characteristics. The unadjusted
and adjusted odds ratio (OR) and 95% Conﬁdence Interval
(CI) were estimated using conditional logistic regression.
Maritalstatus,educationallevel,andBodyMassIndex(BMI)
were considered to be potential confounders and added
sequentially to the regression models.
3. Results
The characteristics of the participants are presented in
Table 1. Cases and controls were matched on age, gender,
and smoking status (Table 1). Ever alcohol consumption
was comparable between cases and controls and so were
pack- and drink-years, variables calculated to describe the
cumulative use of cigarette smoking and alcohol use, respec-
tively. Cases tended to have a lower BMI at the time of the
interviewcomparedtocontrols;howevertheBMI,asrecalled
by the participants 10 years later, was comparable between
the two groups. Cases tended to have a lower educational
levelcomparedtocontrolsand76%ofcontrolsweremarried
or living as married compared to 60% of cases.
Subjects were categorized as either “never”, “occasional”,
or “daily NSAID users”. The distribution of NSAID use
varied between cases and controls, with more cases reporting
never to have used NSAIDs and more controls reporting
daily use of NSAIDs. Seventy percent of cases and 78% of
controls who were daily users of NSAIDs were aspirin users
(Table 1). The main reason for NSAID use in the control
groupwasheartdisease.ThemeanageatinitiationofNSAID
use was 56 for both cases and controls. Cases would more
often have fewer than 2 NSAID tablet years (tablets/day ×
years of use) compared to controls.
Users and nonusers of NSAIDs were compared stratiﬁed
by case status. These two groups did not diﬀer in any
of the parameters examined among controls but diﬀered
signiﬁcantly with respect to age and marital status among
cases (Table 2). More speciﬁcally, cases who were NSAID
users tended to be older and were more likely to be married
or be living as married. We also observed that caseswhowere
NSAID users had a higher age-adjusted BMI compared to
c a s e st h a tw e r en o n u s e r sa n dw o u l dm o r el i k e l yb el i g h t e r
drinkers as estimated by drink-years (Table 2).
The conditional logistic regression analysis showed that
individuals that ever used NSAIDs had a 75% signiﬁcant
reduction in the risk of developing HNSCC (95% CI =
33%–91%). Adjusting for potential confounders like edu-
cational level and marital status (Table 3) or BMI (results
not shown) did not alter the risk estimates. A consistent risk
reduction was noted in association with frequency of NSAID
use when occasional and daily users were compared to never
users (OR for occasional users = 0.37, 95% CI = 0.13–1.04,
OR for daily users = 0.12, 95% CI = 0.04–0.42).International Journal of Otolaryngology 3
Table 1: Characteristics of patients with head and neck cancer and matched controls.
Cases Controls
(N = 71) (N = 71)
Age, mean (SD) 56 (12) 57 (9.7)
Gender, N (%)
Male 61 (86) 61 (86)
Female 10 (14) 10 (14)
Smoking Status, N (%)
Ever 55 (73) 55 (73)
Never 16 (27) 16 (27)
Pack-years, N (%)
<40 14 (26) 15 (27)
41–60 16 (29) 11 (20)
>60 21 (38) 24 (44)
Missing 4 (7) 5 (9)
BMI, mean (SD)
Current 26 (5.3) 28 (4.6)
10 years ago 24 (4.0) 24 (4.0)
Alcohol Consumption, N (%)
Ever 71 (100) 65 (92)
Never 0 (0) 5 (7)
Missing 0 (0) 1 (1)
Drink-years, N (%)
<20 18 (25) 16 (24)
21–40 17 (24) 13 (20)
41–60 9 (13) 9 (14)
>60 24 (34) 18 (28)
Missing 3 (4) 9 (14)
Education level, N (%)
<College 38 (54) 17 (24)
≥College 33 (46) 53 (75)
Missing 0 (0) 1 (1)
Married or living as married, N (%)
Yes 42 (60) 54 (76)
No 28 (39) 17 (24)
Missing 1 (1) 0 (0)
NSAID use, N (%)
Never 25 (35) 10 (14)
Occasional 27 (38) 24 (34)
Daily 19 (27) 37 (52)
Type of NSAID ∗, N (%)
Aspirin 14 (75) 29 (78)
Other 3 (16) 5 (14)
Missing 2 (11) 3 (8)
Reason for using NSAID ∗, N (%)
Headache 2 (11) 0 (0)
Heart disease 9 (47) 24 (65)
Other 7 (37) 11 (30)
Missing 1 (5) 2 (5)4 International Journal of Otolaryngology
Table 1: Continued.
Cases Controls
(N = 71) (N = 71)
Age of NSAID use initiation, mean (SD)∗ 56 (9.4) 56 (9.3)
NSAID tablet years ∗, N (%)
<2 6 (32) 7 (19)
2-3 0 (0) 7 (19)
>3 8 (42) 13 (35)
Missing 5 (26) 10 (27)
∗Among daily users.
Missing data: Current BMI unknown for 2 subjects, 10 years ago unknown for 8 subjects, age at NSAID initiation unknown for 5 subjects.
SD: Standard Deviation.
Table 2: Characteristics of cases and controls by NSAID use. Number (percentage) is shown unless otherwise indicated.
Cases Controls
Never users (N = 25) Ever users (N=46) P-value∗ Never users (N = 10) Ever users (N = 61) P-value∗
Age, years mean (SD) 52 (12) 58 (11) .02 54 (10) 58 (10) .30
Smoking Status .77 .68
Ever 20 (80) 35 (76) 7 (70) 48 (79)
Never 5 (20) 11 (24) 3 (30) 13 (21)
Pack-years .54 .13
<40 6 (30) 8 (23) 3 (43) 12 (25)
40–60 4 (20) 12 (34) 3 (43) 8 (17)
≥60 9 (45) 12 (34) 1 (14) 23 (48)
Unknown 1 (5) 3 (9) 0 (0) 5 (10)
Race .40 .11
Caucasian 19 (76) 40 (87) 8 (80) 47 (77)
African American 5 (20) 4 (9) 0 (0) 10 (16)
Other 1 (4) 2 (4) 2 (20) 4 (7)
Alcohol Consumption —. 5 5
Ever 25 (100) 46 (100) 9 (90) 56 (91)
Never 0 (0) 0 (0) 1 (10) 4 (7)
Unknown 0 (0) 0 (0) 0 (0) 1 (2)
Drink-years .06 .53
<20 4 (16) 14 (31) 3 (34) 13 (24)
20–40 10 (40) 7 (15) 3 (33) 10 (18)
40–60 1 (4) 8 (17) 1 (11) 8 (14)
≥60 9 (36) 15 (33) 1 (11) 17 (30)
Unknown 1 (4) 2 (4) 1 (11) 8 (14)
Current BMI, mean (SE)† 24 (1.1) 27 (0.8) .08 28 (1.5) 28 (0.6) .97
Married or living as married .01 0.99
Yes 10 (40) 32 (70) 8 (80) 46 (75)
No 15 (60) 13 (28) 2 (20) 15 (25)
Unknown 0 (0) 1 (2) 0 (0) 0 (0)
Education level .42 .99
<College 15 (60) 23 (50) 2 (20) 15 (24)
≥College 10 (40) 23 (50) 8 (80) 45 (74)
Unknown 0 (0) 0 (0) 0 (0) 1 (2)
∗P-values were computed using t-tests for continuous characteristics, Fisher’s exact test for categorical characteristics with cell frequencies of 5 or less, and
chi-square tests for all other characteristics. Missing values were excluded from the P-value computation.
†BMI comparisons were age adjusted. Means are shown for a 56-year-old subject.
Missing data: BMI unknown for 1 case and 1 control.
SD: Standard Deviation; SE: Standard Error.International Journal of Otolaryngology 5
Table 3: Unadjusted and Adjusted risk estimated of having Head and Neck Cancer by NSAID use categories.
Cases/Controls OR1 95% CI P-value∗ Cases/Controls OR2 95% CI P-value∗
NSAID use
Never 25/10 1.00 25/10 1.00
Ever 46/61 0.25 (0.09, 0.67) .01 44/59 0.31 (0.11, 0.88) .03
Never 25/10 1.00 25/10 1.00
Occasional 27/24 0.37 (0.13, 1.04) .06 26/23 0.45 (0.15, 1.34) .15
Daily 19/37 0.12 (0.04, 0.42) .001 18/36 0.14 (0.04, 0.54) .004
Aspirin Use
Never User 15/6 1.00 15/6 1.00
Daily Aspirin Use 10/19 0.10 (0.01, 0.78) .03 10/19 0.15 (0.02, 1.3) .09
∗P-values were computed using conditional logistic regression.
OR1: Unadjusted Odds Ratio; OR2: Odds Ratio after adjusting for educational level and marital status.
4. Discussion
Our data suggest that use of NSAIDs is associated with a
signiﬁcant 75% reduction in the risk of developing HNSCC
in a frequency-dependent manner. As the majority of the
study population was aspirin users, the data indicate that
aspirin use, speciﬁcally, may be protective for HNSCC. Our
ﬁndingscorroboratethoseofapreviousstudybyJayaprakash
et al. [21] and support the hypothesis that aspirin use is
associatedwithareducedriskofdevelopingHNSCC.Despite
the issues of temporality associated with the case-control
design, our study provides evidence in favor of the potential
protective eﬀect of NSAIDs in general and aspirin more
speciﬁcally. We cannot overlook the fact that the protective
eﬀect associated with NSAID use estimated in our analysis is
somewhathigherthanthatalreadypublishedpreviously[21]
and that NSAID use may reﬂect the overall healthier lifestyle
of the users.
We examined the association of socioeconomic level,
based on measures of income and education, and marital
status with case status and NSAID use. In agreement with
previous reports, we observed that participants that live
with a partner were more likely to be cancer free and also
be NSAID users compared to those that do not live with
a partner. Studies have reported that married adults are
healthier and live longer than unmarried adults [23, 24]. It
is possible that among the more health conscious subjects
that are also NSAID users, regular consumption of fruits and
vegetables synergizes with NSAID use in lowering the risk
of HNSCC. Cases were of lower educational level compared
to controls. Given the documented associations between
head and neck cancer and socioeconomic status, regular
NSAID use could reﬂect a higher socioeconomic status,
the latter acting as a confounder in the assessment of the
eﬀect of NSAID use on the risk of head and neck cancer
[25–27]. Following adjustment for both marital status and
educational level, the estimate of the protective eﬀect of
NSAIDs remained similar for daily users (OR = 0.12 and
95% CI = (0.04,0.42) before adjustment; OR = 0.14 and
95% CI = (0.04,0.54) after adjustment); it is therefore more
likely that the observed association is real. Other surrogates
of a healthy lifestyle like exercise and diet should be carefully
examined in order to provide more precise estimates of the
independent eﬀect of NSAIDs in HNSCC risk. Moreover,
the dose eﬀects of NSAID use, smoking, and alcohol intake
need to be considered in detail to further clarify the observed
preventive eﬀect.
Leanness has been associated with an increased risk for
cancers of the oral cavity and pharynx [28] and in our
population cases had a lower BMI compared to controls. The
observation was based on weight at the time of the interview;
therefore, we cannot exclude the likelihood that the low BMI
was the result of cancer development. Interestingly, cases
that were NSAID users had an age-adjusted BMI higher
than nonusers and comparable to the control group. The
possibilitythatNSAIDuseingeneral,oraspirininparticular,
among patients with head and neck cancer improves the
quality of life of these patients needs to be investigated with
great care.
As mentioned previously, it is believed that aspirin
exerts a chemopreventive eﬀect on other cancers through
the inhibition of the enzyme COX-2. Cyclooxygenase-2
is a member of family of enzymes called prostaglandin
endoperoxide (PGH) synthases that are involved with cat-
alyzing the formation of prostaglandins (PGs) from the fatty
acid arachadonic acid [29]. Both COX-2 activity and the
products of arachadonic acid metabolism derived via this
pathway have been correlated with the presence of HNSCC
and tumor metastasis. Studies have demonstrated that the
levels of COX-2 and its prostaglandin derivatives, speciﬁcally
prostaglandin E2 (PGE2), are increased in premalignant
and malignant lesions of HNSCC [30]. For instance, COX-
2 messenger RNA is found to have increased activity in
H N S C Cm u c o s av e r s u sn o r m a lm u c o s a ,a n dP G E 2 is found
in increased levels in the tumor milieu and serum of patients
with HNSCC [31, 32]. Elevated levels of PGE2 are also found
in patients with higher stages of cancer and in those with
tumor recurrence [21]. Therefore, there is overwhelming
evidence supporting the increased activity of COX-2 in head
and neck cancer patients.
The overexpression of COX-2 and hence the increased
levels of PGE2 in HNSCC patients could contribute to6 International Journal of Otolaryngology
carcinogenesis via multiple mechanisms. First, through an
increaseinthelevelsoftheantiapoptoticproteinbcl-2,COX-
2 overexpression promotes the survival of premalignant
damaged cells leading to tumorigenesis [33]. Increased levels
of COX-2 expression and PGE2 have also been shown to
induce cell proliferation as well as angiogenesis by increasing
the production of vascular-endothelial growth factor by
epithelial cells [34]. Increased production of PGE2 also
suppresses the immune system of patients with HNSCC by
suppressing lymphokine production, T- and B-lymphocyte
proliferation, and the cytotoxicity of natural killer cells
and macrophages [33]. Metabolites such as PGE2,m a t r i x
metalloproteinase, and thromboxane are also thought to be
associated with increased invasiveness and metastatic poten-
tial of squamous cell cancer [35, 36]. Therefore, through the
inhibitionofCOX-2,NSAIDsreducetheproductionofPGE2
in HNSCC patients and block the downstream pathways that
promote tumorigenesis.
Animal model studies have also demonstrated the
chemopreventive beneﬁts of NSAIDs in HNSCC. A study by
Tanaka et al. [37] involving rats with precancerous lesions
of the tongue revealed that the incidence of HNSCC was
reduced to 23%–31% with the administration of NSAIDs
compared to 71% in rats that did not receive NSAIDs.
Laboratory studies have also shown that NSAIDs increase
the host immune cell inﬁltration in tumor cells [38],
inhibit the growth of squamous cell cancer in mice [39–
41], and cultured human HNSCC cell lines [42]. There has
also been immunohistochemical evidence indicating that
the expression of COX-2 protein in oral mucosal lesions
increasesasthelesionsprogressfromhyperplasiatodysplasia
with the highest levels of COX-2 stain found in SCC. These
studies suggest that the inhibition of COX-2 by NSAIDs has
a signiﬁcant role in the chemoprevention of HNSCC.
In 2002, the US Preventive Services Task Force strongly
recommended that clinicians discuss aspirin use with adults
who are at increased risk of coronary heart disease [43].
The recommendation was based on data from 5 randomized
controlled trials that showed a 28% reduction in risk of
myocardial infarctions with aspirin use. There is a large body
of evidence supporting the chemopreventive role of NSAIDs
in diﬀerent types of cancer although studies that shed doubt
on the chemopreventive eﬀect of NSAIDs should not be
overlooked. Very few case-control studies have investigated
such an eﬀect in HNSCC. Our study adds to this literature
by demonstrating a statistically signiﬁcant 75% reduction in
the risk of developing HNSCC in patients using NSAIDs. We
recommend caution when interpreting our data due to the
possibility of an overestimated protective eﬀect of NSAID
use; we cannot exclude the possibility that people that use
NSAIDsregularlyhaveanoverallhealthierlifestylecompared
to people that do not and that contributes to the protective
eﬀect observed. This study explored the chemopreventive
eﬀects of aspirin as the majority of the population examined
was aspirin users. Despite its limitations and the case-control
design, our research supports the hypothesis that the risk
of HNSCC is reduced in users of NSAIDs especially daily
users and underlies the need for further examination of the
chemopreventive eﬀect of NSAIDs in this disease.
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